Evidence for use of glatiramer acetate in multiple sclerosis
- 1 February 2005
- journal article
- editorial
- Published by Elsevier in The Lancet Neurology
- Vol. 4 (2) , 74-75
- https://doi.org/10.1016/s1474-4422(05)00974-9
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Lack of evidence for use of glatiramer acetate in multiple sclerosisThe Lancet Neurology, 2004
- Glatiramer acetate for the treatment of multiple sclerosisExpert Opinion on Pharmacotherapy, 2004
- Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trialsMultiple Sclerosis Journal, 2003
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disabilityNeurology, 1998
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987
- Rating neurologic impairment in multiple sclerosisNeurology, 1983